Warby Parker Inc. (WRBY) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.05. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.11, delivering a surprise of +22.22%.Over the last four quarters, the company has surpas ...

Key Takeaways Colgate delivered record 2025 sales and free cash flow despite raw material inflation and incremental tariffs.Colgate's SGPP aims to streamline operations and fund the 2030 strategy while driving EPS growth.CL expects 2026 margin expansion via pricing, productivity and revenue-management efforts.Colgate-Palmolive Company (CL) entered 2026 with improved momentum after navigating a volatile 2025, marked by raw-material inflation, incremental tariffs and uneven category growth. Despite these pres ...

Core Insights - CVS Health Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of $1.09, an 8.4% decline year over year, but exceeded the Zacks Consensus Estimate by 10.1% [1][9] - The company's total revenues for the fourth quarter rose 8.2% year over year to $105.69 billion, surpassing the Zacks Consensus Estimate by 2.2% [3][9] - CVS Health's full-year adjusted EPS was $6.75, a 24.5% increase from 2024, beating the Zacks Consensus Estimate by 1.5% [2] Revenue Performance - Health Services revenues increased 9% year over year to $51.24 billion, driven by pharmacy drug mix and brand inflation, despite a 7.5% decline in total pharmacy claims processed [4] - Revenues in the Pharmacy & Consumer Wellness segment rose 12.4% year over year to $37.66 billion, primarily due to increased prescription volume and acquisitions, offset by reimbursement pressure [5] - The Health Care Benefits segment reported revenues of $36.29 billion, up 10.1% year over year, largely due to the Government business and the Inflation Reduction Act's impact on Medicare Part D [6] Margin Analysis - The combined cost of products sold and healthcare costs rose 8.6% to $92.13 billion, while gross profit increased 5.2% to $13.57 billion, leading to a gross margin contraction of 37 basis points to 12.8% [7] - Adjusted operating margin contracted 44 basis points to 1.9%, despite an 8.9% rise in total operating expenses to $11.46 billion [7] Liquidity Position - CVS Health ended 2025 with cash and cash equivalents of $8.45 billion, a slight decrease from $8.59 billion at the end of 2024, while long-term debt increased to $64.57 billion from $64.15 billion [8] Future Guidance - CVS Health provided 2026 adjusted EPS guidance in the range of $7.00-$7.20, with the Zacks Consensus Estimate currently at $7.15 [11] Overall Assessment - CVS Health's fourth-quarter earnings and revenues exceeded estimates, with year-over-year revenue growth across all segments. However, higher costs and expenses led to margin contraction and bottom-line pressure [12]

Core Insights - Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.42, exceeding the Zacks Consensus Estimate by 1.7% and reflecting a year-over-year increase of 4.8% [1] - The company achieved net sales of $2.24 billion for the quarter, a 10.9% increase year over year, surpassing the Zacks Consensus Estimate by 1.9% [3] - Full-year adjusted EPS was $8.20, marking a 2.5% increase year over year and slightly beating the Zacks Consensus Estimate by 0.5% [2] Revenue Performance - ZBH's net sales for the full year reached $8.23 billion, a 7.2% increase year over year, also marginally exceeding the Zacks Consensus Estimate by 0.5% [3] - U.S. sales totaled $1.31 billion for the quarter, up 11.11% year over year, while international sales were $931.2 million, reflecting a 10.6% increase year over year [4] - Revenue growth was observed across all four product categories, with the S.E.T. unit experiencing a notable 20.1% increase year over year at constant currency [5] Margin Analysis - Adjusted gross margin was reported at 64.7%, a contraction of 632 basis points year over year, primarily due to a 35.1% rise in the cost of products sold [7] - Selling, general and administrative expenses rose 16.8% to $872.3 million, while research and development expenses increased by 9.6% to $118.8 million [7] - Adjusted operating margin contracted 821 basis points to 20.5% [7] Cash Position - At the end of the fourth quarter, ZBH had cash and cash equivalents of $591.9 million, an increase from $525.5 million at the end of the fourth quarter of 2024 [9] - Cumulative net cash provided by operating activities was $1.70 billion, up from $1.50 billion in the previous year [9] Future Outlook - For 2026, ZBH expects revenue growth in the range of 2.5-4.5%, with the Zacks Consensus Estimate for revenues at $8.41 billion, indicating a 3.1% year-over-year growth [10] - Adjusted EPS guidance for the full year is projected to be between $8.30 and $8.45, with the Zacks Consensus Estimate for 2025 adjusted EPS at $8.54 [10] Overall Assessment - ZBH's fourth-quarter results exceeded expectations, with growth reported across all business segments [11] - Notable developments contributing to growth include FDA clearance for ROSA Knee and the launch of the Brachiator Mini-Rail External Fixation System [11] - Despite the positive revenue and earnings performance, the contraction in margins presents a concern [11]

Core Insights - Haemonetics Corporation (HAE) reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $1.31, reflecting a year-over-year increase of 10.1% and exceeding the Zacks Consensus Estimate by 3.1% [1][9] - The company's revenues decreased by 2.7% to $339 million, which still surpassed the Zacks Consensus Estimate by 1.4% [2][9] Revenue Breakdown - Plasma segment revenues reached $138.9 million, up 3.5% year over year, with organic growth of 2.8%, driven by strong demand for immunoglobulin [3] - Blood Center revenues fell 19.6% to $56.6 million, although organic growth was 2.8%, supported by international Plasma demand [4] - Hospital revenues slightly decreased by 0.3% to $143.5 million, with a 0.9% decline on an organic basis [4] Margin Performance - Gross profit increased by 4.6% to $202.4 million, with gross margin expanding by 418 basis points to 59.7% due to an 11.9% decline in the cost of sales [6] - Operating profit rose to $79 million, compared to $71.3 million in the prior year, with an operating margin increase of 287 basis points to 23.3% [7][9] Financial Position - At the end of the third quarter, Haemonetics had cash and cash equivalents of $363.4 million, up from $296.4 million at the end of the previous quarter [8] - Long-term debt remained stable at $920 million, and cumulative net cash flow from operating activities increased to $222.3 million from $65.2 million a year ago [8] Guidance - The company now expects fiscal 2026 GAAP revenues to decline by 1-3%, with organic revenue growth anticipated in the range of 0-2% compared to fiscal 2025 [10] - Adjusted EPS guidance for full-year 2026 is set between $4.90 and $5.00, up from the previous range of $4.80 to $5.00 [11] Overall Assessment - Haemonetics demonstrated better-than-expected results in the fiscal third quarter, with earnings and revenues surpassing estimates despite a year-over-year revenue decline [12] - The performance highlights the strength of the company's core businesses, particularly in Blood Management Technologies and Plasma, while targeted actions are planned to improve Interventional Technologies [12][13]

Core Insights - STERIS plc reported third-quarter fiscal 2026 adjusted earnings per share (EPS) of $2.53, reflecting a 9% increase year-over-year, matching the Zacks Consensus Estimate [2][9] - The company's GAAP EPS was $1.96, up 12% from $1.75 in the previous year [2] Revenue Performance - Total revenues from continuing operations reached $1.50 billion, marking a 9.5% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.1% [3][9] - Organic revenues at constant exchange rate (CER) rose by 8% year-over-year [3] - Revenue breakdown by segment: - Healthcare segment revenues increased by 9% to $1.10 billion, with service revenues up 11%, consumable revenues up 8%, and capital equipment revenues up 7% [4] - Applied Sterilization Technologies (AST) revenues improved by 11% to $286.6 million, driven by 9% growth in service revenues and a significant 103% increase in capital equipment revenues [5] - Life Sciences segment revenues rose by 7% to $145.8 million, with consumable revenues up 11% and capital equipment revenues up 7% [6] Margin Analysis - Gross profit for the quarter was $655.5 million, a 7.4% increase from the prior year, but gross margin contracted by 72 basis points to 43.8% due to a 10.6% rise in the cost of revenues [7] - Selling, general and administrative expenses rose by 5% to $352.3 million, while research and development expenses increased by 7.7% to $29.5 million [8] Financial Guidance - STERIS maintained its fiscal 2026 guidance, expecting revenue growth of approximately 8-9% and adjusted EPS in the range of $10.15-$10.30 [11] - The Zacks Consensus Estimate for revenues is $5.93 billion, implying an 8.6% growth from fiscal 2025 [11] Overall Assessment - The company ended the third quarter on a mixed note, with earnings meeting estimates and revenues exceeding expectations, while all business segments experienced growth [12] - Despite increased costs impacting gross margins, the expansion of operating margins is viewed positively for the stock [12]

Core Insights - Boston Scientific Corporation (BSX) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 80 cents, a 14.3% increase from the previous year, surpassing the Zacks Consensus Estimate by 2.6% and exceeding the company's guidance of 77-79 cents [1][2] - The company's full-year adjusted EPS reached $3.06, marking a 21.9% increase from 2024, also exceeding the Zacks Consensus Estimate by 0.7% and the 2025 guidance range of $3.02-$3.04 [2] Revenue Performance - Fourth-quarter revenues totaled $5.29 billion, reflecting a 15.9% year-over-year increase on a reported basis and 14.3% on an operational basis, with organic growth of 12.7% [3] - For the full year 2025, revenues were $20.07 billion, up 19.9% on a reported basis, 19.2% operationally, and 15.8% organically compared to 2024 [4] Regional Revenue Breakdown - In Q4, revenues increased by 17% in the United States, 12.4% in Europe, the Middle East and Africa (EMEA), 15.2% in the Asia Pacific, and 15.9% in Latin America and Canada [5] Segment Performance - MedSurg revenues in Q4 were $1.81 billion, up 15.9% year over year, with Endoscopy generating $760 million (8.2% organic growth) and Urology revenues at $717 million (3.2% organic growth) [7] - The Cardiovascular segment generated $3.48 billion in Q4 revenues, an 18.2% increase reported and 16.1% organically year over year [10] Margin Analysis - The gross margin expanded by 172 basis points to 69.6%, while adjusted operating margin increased by 180 basis points to 24% despite rising costs [11] Future Outlook - For 2026, Boston Scientific anticipates net sales growth of approximately 10.5-11.5% on a reported basis and 10-11% organically, with adjusted EPS expected in the range of $3.43-$3.49 [12] - Q1 2026 revenue growth is projected at 10.5-12% on a reported basis and 8.5-10% organically, with adjusted earnings expected between 78-80 cents per share [13] Strategic Developments - The company achieved broad regulatory approvals and clinical milestones across various franchises, including strategic acquisitions to enhance its vascular and neuromodulation portfolio [15]

Core Insights - Bio-Techne Corporation (TECH) reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 46 cents, exceeding the Zacks Consensus Estimate by 8.2% and reflecting a year-over-year increase of 9.5% [1] - The company's net sales for the quarter were $295.9 million, showing a slight decline of 0.4% year over year, but surpassing the Zacks Consensus Estimate by 1.3% [2] - The operating profit for the quarter was $54.5 million, an increase from $47.4 million in the prior year, with the operating margin expanding by 244 basis points to 18.4% [6][8] Revenue Breakdown - In the Protein Sciences segment, Bio-Techne recorded revenues of $215.1 million, a 2% increase year over year, although it was down 1% on an organic basis [3] - The Diagnostics and Spatial Biology segment saw a revenue decrease of 4% year over year to $81.2 million, but it increased by 3% on an organic basis [4] Margin Analysis - Gross profit fell by 1.3% to $191.3 million, with the gross margin contracting by 63 basis points to 64.6% due to a 1.4% rise in the cost of sales [5] - Selling, general and administrative expenses decreased by 6.4% to $113.7 million, while research and development expenses totaled $23.1 million, down 7.6% year over year [5] Financial Position - At the end of the fiscal second quarter, Bio-Techne had cash and equivalents of $172.9 million, up from $145 million at the end of the previous quarter, while long-term debt obligations decreased to $260 million from $300 million [7] Overall Performance - Despite a quarterly revenue decline and gross margin contraction, there are signs of stabilization in the U.S. academic market, improving performance in biotech, ongoing growth in Asia, and continued strength among large pharmaceutical customers [10]

分组1 - Church & Dwight reported quarterly earnings of $0.86 per share, exceeding the Zacks Consensus Estimate of $0.84 per share, and showing an increase from $0.77 per share a year ago, resulting in an earnings surprise of +2.77% [1] - The company achieved revenues of $1.64 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 0.39%, and up from $1.58 billion year-over-year [2] - Church & Dwight has outperformed the S&P 500 with a share price increase of about 9.7% since the beginning of the year, compared to the S&P 500's gain of 1.8% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.95 on revenues of $1.52 billion, and for the current fiscal year, it is $3.73 on revenues of $6.31 billion [7] - The Zacks Industry Rank indicates that the Consumer Products - Staples sector is in the bottom 32% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

Core Insights - National Vision Holdings, Inc. is leveraging its retail brands to enhance customer experience and operational efficiency across its extensive network of over 1,200 stores in 38 states and Puerto Rico [1][3] Company Overview - National Vision Holdings, Inc. operates four retail brands: America's Best Contacts & Eyeglasses, Eyeglass World, Vista Optical, and DiscountContacts.com, focusing on making quality eye care and eyewear more affordable and accessible [3] - The company is committed to using data-driven insights to improve customer experiences in its stores [1] Leadership Profile - Alex Wilkes, who became CEO in August 2025, has over a decade of leadership experience in the eye care industry and is focused on enhancing customer and patient experiences while driving long-term shareholder value [2] - Prior to joining National Vision, Alex held significant roles at CooperVision and EssilorLuxottica, contributing to operational excellence and brand strategy [2]